Aurobindo Pharma's net debt to equity ratio FY 2013-2023

Published by A. Minhas, Aug 28, 2023
In fiscal year 2023, Aurobindo Pharma Limited had negative 0.05 debt to equity ratio, which was a slight increase from the previous financial year. The pharmaceutical company recorded a revenue of over 248 billion Indian rupees in financial year 2023.

Net debt to equity ratio of Aurobindo Pharma Limited from financial year 2013 to 2023

© Statista 2024
Download
Show detailed source information?
Register for free
Already a member?
Log in
Source

Use Ask Statista Research Service

Release date

August 2023

Region

India

Survey time period

FY 2013 to FY 2023

Supplementary notes

The net debt to equity ratio is an important metric used to assess the degree to which a company is financing its operations through debt versus wholly owned funds.
*Includes higher sales from limited competition product.
India's fiscal year starts in April and ends in March. For example, FY 2018 started in April 2017 and ended in March 2018.

Citation formats
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interest

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

    • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams up to 5 people
$959 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts

Statistics on " Zoetis "

The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics

Other statistics that may interest you Zoetis

Overview

4

Revenue figures

4

Revenue distribution

4

Competitors

4

Other key data

5

Further related statistics

9

Further Content: You might find this interesting as well

Statistics

Topics

Merck & Co.Global pharmaceutical industryPharmaceutical industry in the U.S.Top pharmaceutical drugsPfizer
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interest

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

    • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams up to 5 people
$959 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts
Learn more about how Statista can support your business.
Menu